Introduction {#s1}
============

Nesfatin-1~1−82~ was discovered in 2006 by Mori et al. as an anorexigenic peptide derived from the rat brain (Oh-I et al., [@B22]). It is post-translationally processed from the gene encoding nucleobindin2 (NUCB2) by the pro-hormone-convertase 1/3 (Oh-I et al., [@B22]). NUCB2 consists of a 24 amino acid N-terminal signal peptide and a protein structure containing 396 amino acids, but only the 396 amino acid sequence is cleaved into the N-terminal nesfatin-1~1−82~, nesfatin-2~85−163~, and the C-terminal nesfatin-3~166−396~ (Oh-I et al., [@B22]). It was shown that nesfatin-1~1−82~, but not nesfatin-2~85−163~ or nesfatin-3~166−396~, reduces food intake and body weight gain in rats after injection into the third brain ventricle (Oh-I et al., [@B22]). The anorexigenic effect of central nesfatin-1~1−82~ injected into the lateral, third and fourth brain ventricle, into the cisterna magna or directly into the lateral hypothalamic area, the paraventricular nucleus, or the dorsal vagal complex has been confirmed by various independent groups in several studies in rats (Yosten and Samson, [@B40], [@B41]; Chen et al., [@B7]; Könczöl et al., [@B17]; Xia et al., [@B38]; Dong et al., [@B9]), mice (Atsuchi et al., [@B3]; Goebel et al., [@B12]), and goldfish (Gonzalez et al., [@B13]; Kerbel and Unniappan, [@B16]). This converging evidence points toward a physiological role of nesfatin-1~1−82~ in the regulation of food intake.

Following these initial studies, the anorexigenic effect of nesfatin-1 was further characterized investigating the underlying food intake microstructure providing deeper insight into the mechanisms underlying the reduction of food intake (Geary, [@B11]). In mice, nesfatin-1~1−82~ injected intracerebroventricularly (icv) reduced food intake with a delayed onset, an effect due to a reduction in meal size and meal frequency (Goebel et al., [@B12]) indicating a stimulatory effect on satiation and satiety (Strubbe and Woods, [@B35]). However, as species differences often play a role, this characterization is pending in rats.

Recently, the active core of nesfatin-1~1−82~ has been identified, namely the mid fragment nesfatin-1~30−59~ (Shimizu et al., [@B26]), while the N-terminal nesfatin-1~1−29~, and the C-terminal nesfatin-1~60−82~ had no anorexigenic effect in mice (Shimizu et al., [@B26]; Stengel et al., [@B31]). Although it is not clear yet whether this processing occurs *in vivo*, the characterization is an important step toward a better understanding of the ligand-receptor interaction, keeping in mind that the nesfatin-1 receptor remains to be identified. Again, the characterization of the anorexigenic effect of nesfatin-1~30−59~ is lacking for rats.

After the initial identification of NUCB2/nesfatin-1 in the brain, NUCB2 mRNA, and NUCB2/nesfatin-1 protein expression was also detected in the periphery (Stengel et al., [@B30]). Interestingly, the major source of NUCB2/nesfatin-1 is the stomach with much higher NUCB2 mRNA expression levels compared to the brain (Stengel et al., [@B30]) likely to act as a gut-brain peptide, a hypothesis supported by the observation that nesfatin-1 is able to cross the blood-brain barrier (Pan et al., [@B23]). Interestingly, on a cellular level NUCB2/nesfatin-1 is co-expressed with ghrelin, the major orexigenic peptide signaling from the gut to the brain (Al Massadi et al., [@B1]), within the same cells in rats (Stengel et al., [@B30]), and humans (Stengel et al., [@B32]). This led to the assumption that these endocrine cells in the stomach can regulate food intake in both directions, either stimulate *via* the release of ghrelin or inhibit *via* the release of NUCB2/nesfatin-1 (Stengel and Taché, [@B34]). However, data on the peripheral effects of nesfatin-1 on food intake are inconsistent. While several studies observed no effects of nesfatin-1 on food intake in rats (Stengel et al., [@B28]) or mice (Goebel et al., [@B12]), one study described an anorexigenic effect of nesfatin-1~30−59~ following intraperitoneal (ip) injection of high doses in mice (Shimizu et al., [@B26]). However, no data in rats exist so far.

The therapeutic potential of NUCB2/nesfatin-1 was discussed in several review articles (Stengel et al., [@B33]), especially in the light of its leptin-independent signaling pathway (Oh-I et al., [@B22]), a hormone known to be less active under conditions of obesity (also known as leptin resistance) (Crujeiras et al., [@B8]). However, a detailed characterization of the food intake microstructure under conditions of diet-induced obesity (DIO), a well-established animal model for alimentary obesity (Lutz and Woods, [@B18]) frequently found in humans, has not been performed yet.

Therefore, the aims of the current study were to investigate the effect of icv injected nesfatin-1~30−59~ on the food intake microstructure in normal weight rats. Next, we investigated whether the effect could also be observed following ip injection in rats. Lastly, to characterize the effect of nesfatin-1~30−59~ on the food intake microstructure in obese animals, DIO rats fed a high fat diet were generated and nesfatin-1~30−59~ injected icv.

Materials and methods {#s2}
=====================

Animals
-------

Male Sprague--Dawley rats (Harlan-Winkelmann Co., Borchen, Germany) weighing 280--350 g were first group housed (4 rats/group) under controlled illumination (06.00--18.00 h) and temperature (21--23°C). During this time rats were handled daily to become accustomed to the interaction with the investigators (daily control of body weight, light hand restraint for subsequent icv, or ip injections). Rats had *ad libitum* access to standard rodent diet (D12450B, Research Diets, Inc., Jules Lane, New Brunswick, NJ, USA) and tap water. Animal care and experimental procedures followed institutional ethics guidelines, conformed to the requirements and were approved by the state authority for animal research conduct (Landesamt für Gesundheit und Soziales Berlin, LaGeSo Berlin; animal protocol \# G 0131/11).

Peptides
--------

Rat nesfatin-1~30−59~ (Bachem AG, Weil am Rhein, Germany) was aliquoted in sterile distilled water and stored at --80°C until further use. Purity was assessed by HPLC and mass spectroscopy (manufacturer\'s information). Directly before administration, rat nesfatin-1~30−59~ was further diluted in sterile ddH~2~O for icv injection or in sterile 0.9% saline (B. Braun AG, Melsungen, Germany) for ip injection to reach the final concentrations detailed below.

Diets
-----

For the induction of DIO, rats were fed a high fat diet (D12451, 45% calories from fat, 35% from carbohydrates, and 20% from protein, 4.7 kcal/g diet, Research Diets Inc.) for a period of 10 weeks. Control rats were kept on a standard rodent diet (D12450B, 10% calories from fat, 70% from carbohydrates, and 20% from protein, 3.9 kcal/g diet, Research Diets Inc.). Body weight and food intake were assessed daily. At the end of the 10-week feeding period, the 50% of rats gaining the most body weight were selected as DIO.

Intracerebroventricular cannulation
-----------------------------------

Rats were chronically icv cannulated as described before (Stengel et al., [@B27],[@B29]). Briefly, rats were anesthetized with an ip injection of 100 mg/kg ketamine (Ketanest™, Curamed, Karlsruhe, Germany) and 10 mg/kg xylazine (Rompun™, 2%, Bayer, Leverkusen, Germany). Afterwards, rats were placed in a stereotactic apparatus to implant a chronic 22-gauge guide cannula into the right lateral brain ventricle. The coordinates for the placement (from bregma: 0.8 mm posterior, 1.5 mm right lateral, and 3.5 mm ventral) were based on the atlas of Paxinos and Watson ([@B24]). The chronic 22-gauge guide cannula was fixed by dental cement, anchored by four sterile screws (Plastic One Inc., Roanoke, VA, USA), and the wound was sutured. After the surgery, animals were housed individually and allowed to recover for 5 days. During this time, rats were handled daily to adapt to the icv injection procedure (light hand restraint for 1 min). For the icv injection a 28-gauge cannula was connected to a 25 μl Hamilton syringe by a PE-50 tube (BD intramedic polyethylene tubing, Clay Adams, NJ, USA) and a volume of 5 μl was injected over a period of 1 min into the conscious rat.

The correct placement of the cannula was verified after the experiments by injecting 5 μl of 0.1% toluidine blue and visualizing the spreading of the dye throughout the brain ventricular system. No animals had to be excluded due to erroneous placement of the cannula.

Automated food intake monitoring
--------------------------------

The BioDAQ episodic food intake monitoring system (BioDAQ, Research Diets Inc.) was used to investigate the food intake microstructure in rats. This system has been established before for the use in mice (Goebel et al., [@B12]) and recently also rats (Teuffel et al., [@B36]).

Rats were habituated for 1 week to the single housing (in regular housing cages with normal bedding and enrichment) and feeding from the hopper and as shown before quickly adapted to these conditions within 2--3 days indicated by normal food intake and regular body weight gain (Teuffel et al., [@B36]). Water was provided *ad libitum* from regular water bottles. Food was provided in low spill food hoppers placed on a balance. The "bridging phenomenon," that occurs when retained food spillage underneath the gate causes erroneous measurements, was observed very rarely by use of the diet described above and daily maintenance (cleaning) of the hoppers.

The BioDAQ food intake monitoring system weighs the hopper with food (±0.01 g) every second and detects "not eating" as weight stable and "eating" as weight unstable. "Feeding bouts," defined as change in stable weight before and after an event, are recorded as vectors with starting time, duration and amount of food consumed (Teuffel et al., [@B36]). The feeding bouts are separated by an inter-bout interval (IBI) and meals can consist of one or more bouts. Furthermore, meals are separated by inter-meal intervals (IMI), in rats defined by a duration of 15 min (Teuffel et al., [@B36]). The minimum meal size in rats was defined as 0.01 g and therefore food intake was considered as one meal when the feeding bouts occurred within 15 min of the previous response and the content of food was equal to or greater than 0.01 g (Teuffel et al., [@B36]). If the interval between meals was greater than 15 min, the feeding bouts were considered as a new meal. Meal parameters assessed in this study encompassed bout size (g/bout), meal size (g/meal), bout frequency (number/period), meal frequency (number/period), inter-meal interval (min), meal duration (min/meal), eating rate (mg/min), time spent in meals (%) as well as the satiety ratio (min/g food eaten) calculated using the parameters described above. These parameters were extracted from the software and visualized using the Data Viewer (BioDAQ Monitoring Software 2.3.07, Research Diets Inc.). Data analysis was performed in Excel (Microsoft). For better comparability between rats fed control or high fat diet, food intake was expressed in kcal/300 g body weight (bw).

Experimental protocols {#s3}
======================

Food intake experiments
-----------------------

In the first experiment icv cannulated rats fed *ad libitum* with standard rodent diet and accustomed to the food intake monitoring system as described above were icv injected with nesfatin-1~30−59~ (0.1, 0.3, or 0.9 nmol/rat) or vehicle (5 μl ddH~2~O) directly before the onset of the dark phase. The dose of nesfatin-1~30−59~ was based on our previous study in mice (Stengel et al., [@B31]). The food intake microstructure was assessed over a period of 24 h. The experiment was repeated once in a crossover design; rats were allowed to recover for 5 days in between the experiments. During two experiments, behavior was determined by observation of the locomotor activity and grooming (including washing and licking).

In order to assess whether the effect of nesfatin-1~30−59~ is also mediated peripherally, naïve rats accustomed to the food intake monitoring system, handled for ip injections and fed *ad libitum* with standard rodent diet were injected ip with nesfatin-1~30−59~ (8.1, 24.3, or 72.9 nmol/kg) or vehicle (300 μl saline) directly before the dark phase started. These doses were based on the observation that higher doses are required peripherally compared to brain injections (Shimizu et al., [@B26]). Therefore, up to 30-times higher doses were used peripherally compared to our icv experiments. The microstructure was assessed over a period of 24 h. This experiment was repeated once in a crossover design. Rats were allowed to recover for 5 days in between the experiments.

Since the hypothalamic regulation of food intake is altered under conditions of DIO (Velloso and Schwartz, [@B37]), we also investigated the effect of nesfatin-1~30−59~ on the food intake microstructure in chronically icv cannulated DIO rats accustomed to the food intake monitoring system and fed a high fat diet. Nesfatin-1~30−59~ (0.9 nmol/rat, dose based on first experiment of the present study) or vehicle (5 μl ddH~2~O) were injected icv directly at the beginning of the dark phase and the food intake microstructure was assessed over a period of 24 h. The experiment was repeated once in a crossover design and rats were allowed to recover for 5 days in between the experiments.

Statistical analysis
--------------------

Distribution of the data was determined by using the Kolmogorov-Smirnov test. Data are expressed as mean ± sem and were analyzed by One-way analysis of variance (ANOVA) followed by Tukey *post hoc* test or Two-way or Three-way ANOVA followed by the Holm--Sidak method. Differences between groups were considered significant when *p* \< 0.05 (SigmaStat 3.1., Systat Software, San Jose, CA, USA).

Results {#s4}
=======

Nesfatin-1~30−59~ injected intracerebroventricularly at the onset of the dark phase reduces food intake by decreasing meal size in normal weight rats
-----------------------------------------------------------------------------------------------------------------------------------------------------

Nesfatin-1~30−59~ (0.1, 0.3, or 0.9 nmol/rat) injected icv in normal weight rats fed *ad libitum* with standard rodent diet induced a dose-related reduction of dark phase food intake with a delayed onset between the 4--8 h period post injection and observed at a dose of 0.9 nmol/rat compared to vehicle (5 μl ddH~2~O, −29%, *p* \< 0.05; Figure [1A](#F1){ref-type="fig"}). Therefore, this dose was used for all further analyses. This reduction resulted in a decrease of cumulative food intake which was observed over the 24-h measurement period (−12% vs. vehicle, *p* \< 0.05; Figure [1B](#F1){ref-type="fig"}) indicating a long-lasting effect. Two-way ANOVA showed a significant influence of dose \[*F*~(3,\ 239)~ = 11.2, *p* \< 0.001\] and time \[*F*~(5,\ 239)~ = 109.2, *p* \< 0.001\].

![**Nesfatin-1~30−59~ reduces food intake for 24 h in ***ad libitum*** fed normal weight rats**. Nesfatin-1~30−59~ injected intracerebroventricularly (0.1, 0.3, and 0.9 nmol/rat) decreases dark phase food intake of standard rodent diet between the fourth and eighth hour and reduces cumulative food intake for 24 h post injection at a dose of 0.9 nmol/rat. Food intake was measured by an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g bw)/4 h periods **(A)** and cumulative food intake over a period of 24 h **(B)**. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 vs. vehicle.](fnins-09-00422-g0001){#F1}

Analysis of hourly food intake indicated that the main anorexigenic effect occurred during the fifth hour post injection with a −75% reduction of food intake following nesfatin-1~30−59~ compared to vehicle (*p* = 0.05; Figure [2](#F2){ref-type="fig"}). Moreover, parameters of the first meal were mostly unaffected by icv nesfatin-1~30−59~ (Table [1](#T1){ref-type="table"}) further pointing toward a delayed onset of the anorexigenic action. However, the interval following the first meal was prolonged by nesfatin-1~30−59~ compared to vehicle (+48%, *p* \< 0.05; Table [1](#T1){ref-type="table"}). Due to the significant reduction of food intake during the 4--8 h period post injection, the underlying food intake microstructure was analyzed during this period. Nesfatin-1~30−59~ (0.9 nmol/rat icv) reduced meal size (−45%, *p* \< 0.05; Figure [3B](#F3){ref-type="fig"}), meal duration (−54%, *p* \< 0.05; Figure [3F](#F3){ref-type="fig"}), and the time spent in meals (−41%, *p* \< 0.05; Figure [3H](#F3){ref-type="fig"}), while bout size (Figure [3A](#F3){ref-type="fig"}), bout frequency (Figure [3C](#F3){ref-type="fig"}), meal frequency (Figure [3D](#F3){ref-type="fig"}), inter-meal intervals (Figure [3E](#F3){ref-type="fig"}), and eating rate (Figure [3G](#F3){ref-type="fig"}) were not significantly affected compared to vehicle (*p*\>0.05). At the same time, the satiety ratio was increased following nesfatin-1~30−59~ compared to vehicle injected icv (+174%, *p* \< 0.05; Figure [3I](#F3){ref-type="fig"}). Manual observation indicated no abnormal behavior following icv injection of nesfatin-1~30−59~ (data not shown).

![**Nesfatin-1~30−59~ reduces food intake during the fifth hour post injection in normal weight rats**. In rats fed *ad libitum* with standard rat diet, nesfatin-1~30−59~ injected intracerebroventricularly (0.1, 0.3, and 0.9 nmol/rat) induces a dose-related decrease in dark phase food intake during the fifth hour post injection reaching significance at 0.3 and 0.9 nmol/rat. Food intake is expressed as hourly food intake (kcal/300 g bw) during the 4--8 h period post injection. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 vs. vehicle.](fnins-09-00422-g0002){#F2}

###### 

**Nesfatin-1~30−59~ injected icv before the dark phase does not alter the parameters of the first meal in ***ad libitum*** fed normal weight rats**.

  **Parameter**                                                   **Group**    
  --------------------------------------------------------------- ------------ ---------------------------------------------
  Latency to first meal (min)                                     2.09±0.55    1.88±0.58
  Size of first meal (kcal/300 g bw)                              5.85±0.84    7.73±0.90
  Duration of first meal (min)                                    10.09±1.64   13.54±1.68
  Eating rate of first meal (cal/300 g bw/min)                    35.80±3.94   29.69±2.86
  Inter-meal interval (min)                                       46.71±6.44   69.32±4.59[^\*^](#TN1){ref-type="table-fn"}
  Satiety ratio after first meal (min/kcal/300 g bw food eaten)   9.16±1.53    11.80±1.93

icv, intracerebroventricular; mean ± sem; n = 10--11/group;

*p \< 0.05*.

![**Nesfatin-1~30−59~ reduces meal size, while meal frequency is not altered in normal weight rats**. Nesfatin-1~30−59~ (0.1, 0.3, and 0.9 nmol/rat) or vehicle (5 μl ddH~2~O) was injected intracerebroventricularly and the food intake microstructure assessed using an automated episodic food intake monitoring system. Due to the strongest reduction in food intake, the dose of 0.9 nmol/rat was used for all further analyses. During the period of 4--8 h post injection, nesfatin-1~30−59~ reduced meal size **(B)**, meal duration **(F)** and the time spent in meals **(H)**, while bout size **(A)**, bout frequency **(C)**, meal frequency **(D)**, inter-meal intervals **(E)** and eating rate **(G)** were not altered compared to vehicle. The satiety ratio was increased following nesfatin-1~30−59~ **(I)**. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 vs. vehicle.](fnins-09-00422-g0003){#F3}

Nesfatin-1~30−59~ injected intraperitoneally at the onset of the dark phase does not reduce food intake or alter the food intake microstructure of normal weight rats
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Nesfatin-1~30−59~ (8.1, 24.3, or 72.9 nmol/kg, ip) injected at higher doses at the onset of the dark phase did not robustly reduce food intake either expressed as food intake/period or cumulative food intake compared to vehicle (*p*\>0.05; Table [2](#T2){ref-type="table"}). Only the highest dose (72.9 nmol/kg, ip) led to a slight and short-lasting reduction of food intake during the seventh hour post injection compared to vehicle (*p* \< 0.05) that did not translate into a reduction of cumulative food intake (*p*\>0.05; Table [2](#T2){ref-type="table"}). Also analysis of the food intake microstructure in the 4--8 h period (the period when nesfatin-1~30−59~ injected icv exerted its main effects) indicated no alterations of microstructural parameters compared to vehicle injected ip (*p*\>0.05; Table [3](#T3){ref-type="table"}). Lastly, parameters of the first meal were not affected by nesfatin-1~30−59~ injected ip compared to control (*p*\>0.05; Table [4](#T4){ref-type="table"}).

###### 

**Nesfatin-1~30−59~ injected ip before the dark phase does not alter food intake in ***ad libitum*** fed normal weight rats**.

  **Period**                                   **Group**                               
  -------------------------------------------- ------------ ------------ ------------- -------------
  **FOOD INTAKE PER PERIOD (KCAL/300 G BW)**                                           
  0--4 h                                       41.15±2.20   44.00±2.47   44.42±2.21    44.48±2.22
  4--8 h                                       27.70±2.09   22.06±2.54   25.80±2.24    27.39±1.78
  8--12 h                                      13.15±2.03   19.61±2.10   15.56±2.47    17.33±2.24
  12--16 h                                     0.47±0.32    0.63±0.45    1.59±1.06     2.85±1.48
  16--20 h                                     1.21±0.78    0.32±0.28    1.31±0.90     0.78±0.71
  20--24 h                                     12.51±1.28   10.48±0.81   12.54±1.78    10.83±0.91
  **CUMULATIVE FOOD INTAKE (KCAL/300 G BW)**                                           
  0--4 h                                       41.15±2.20   44.00±2.47   44.42±2.21    44.48±2.22
  0--8 h                                       68.84±2.56   66.05±2.30   70.23±2.33    71.86±3.16
  0--12 h                                      81.99±2.76   85.67±2.61   85.79±2.74    89.19±3.36
  0--16 h                                      82.47±2.69   86.29±2.68   87.38±2.44    92.05±3.32
  0--20 h                                      83.67±2.79   86.62±2.64   88.69±2.35    92.82±3.45
  0--24 h                                      96.18±2.91   97.09±2.57   101.23±2.36   103.65±3.30

*ip, intraperitoneal; mean ± sem; n = 14/group; p \> 0.05*.

###### 

**Nesfatin-1~30−59~ injected ip before the dark phase does not alter the food intake microstructure in the 4--8 h period post injection in ***ad libitum*** fed normal weight rats**.

  **Parameter**                                         **Group**                                    
  ----------------------------------------------------- -------------- -------------- -------------- --------------------------------------------
  Food intake 4--5 h (kcal/300 g bw)                    5.96±2.13      6.09±2.15      5.26±2.06      8.35±2.87
  Food intake 5--6 h (kcal/300 g bw)                    3.22±2.09      4.21±1.98      6.95±2.52      12.20±3.31
  Food intake 6--7 h (kcal/300 g bw)                    14.18±3.34     5.76±1.97      6.63±2.89      4.29±1.99[^\*^](#TN2){ref-type="table-fn"}
  Food intake 7--8 h (kcal/300 g bw)                    4.34±2.00      6.00±2.54      6.97±2.25      2.53±1.50
  Bout size 4--8 h (kcal/300 g bw)                      0.86±0.06      0.82±0.07      0.87±0.04      0.85±0.05
  Meal size 4--8 h (kcal/300 g bw)                      17.01±2.39     14.32±1.58     15.35±2.25     18.55±2.11
  Bout frequency 4--8 h (number)                        32.07±3.39     27.29±1.99     31.00±2.86     32.64±2.83
  Meal frequency 4--8 h (number)                        1.93±0.22      1.71±0.27      2.00±0.23      1.71±0.19
  Inter-meal interval 4--8 h (min)                      143.61±31.10   101.41±18.08   147.27±27.32   159.46±31.92
  Meal duration 4--8 h (min)                            53.67±8.20     47.36±7.52     48.12±8.75     57.40±7.42
  Eating rate 4--8 h (cal/300 g bw/min)                 109.27±10.94   123.77±11.05   107.61±11.40   125.47±18.96
  Time spent in meals 4--8 h (%)                        36.65±3.17     29.40±3.94     31.89±3.01     35.49±3.43
  Satiety ratio 4--8 h (min/kcal/300 g bw food eaten)   8.17±1.08      7.73±1.66      10.33±1.41     8.47±10.4

ip, intraperitoneal; mean ± sem; n = 14/group;

*p \< 0.05 vs vehicle*.

###### 

**Nesfatin-1~30−59~ injected ip before the dark phase does not alter parameters of the first meal in ***ad libitum*** fed normal weight rats**.

  **Parameter**                                                   **Group**                                    
  --------------------------------------------------------------- -------------- -------------- -------------- --------------
  Latency to first meal (min)                                     4.83±2.24      9.23±3.67      4.74±1.84      7.40±5.39
  Size of first meal (kcal/300 g bw)                              11.08±1.59     7.70±0.85      8.55±1.26      14.00±2.92
  Duration of first meal (min)                                    21.15±3.84     16.95±3.24     17.70±4.17     29.35±8.89
  Eating rate of first meal (cal/300 g bw/min)                    156.85±12.37   152.62±17.56   134.24±13.45   176.78±17.44
  Inter-meal interval (min)                                       48.17±6.94     36.54±4.90     43.12±3.20     49.28±7.17
  Satiety ratio after first meal (min/kcal/300 g bw food eaten)   5.04±0.57      5.72±1.19      9.08±3.49      4.40±0.57

*ip, intraperitoneal; mean ± sem; n = 14/group; p \> 0.05*.

Nesfatin-1~30−59~ injected intracerebroventricularly at the onset of the dark phase reduces food intake by decreasing meal frequency of diet-induced-obese rats fed a high fat diet
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Rats fed a high fat diet (45% calories from fat) for a period of 10 weeks developed DIO and gained significantly more body weight compared to rats fed standard rodent diet (10% calories from fat; +21% at 10 weeks, *p* \< 0.01; Figure [4](#F4){ref-type="fig"}).

![**Rats fed a high fat diet develop diet-induced obesity**. Rats were ***ad libitum*** fed either a high fat diet (45% calories from fat, 35% from carbohydrates, and 20% from protein, 4.7 kcal/g) or standard rodent diet (10% calories from fat, 70% from carbohydrates, and 20% from protein, 3.9 kcal/g) over a period of 10 weeks. Rats that gained most body weight (\~50%) were selected for the following experiments as diet-induced obese (DIO) rats. DIO rats showed greater body weight gain compared to rats fed standard rodent diet. Data are expressed as mean ± sem. ^\*^*p* \< 0.05 and ^\*\*^*p* \< 0.01 vs. vehicle.](fnins-09-00422-g0004){#F4}

When injected icv in DIO rats, nesfatin-1~30−59~ (0.9 nmol/rat) induced a reduction of food intake during the 0--4 h period post injection compared to vehicle (5 μl ddH~2~O, −40%, *p* \< 0.001; Figure [5A](#F5){ref-type="fig"}). This reduction resulted in a decrease of cumulative food intake over a period of 20 h (−13% vs. vehicle, *p* \< 0.05; Figure [5B](#F5){ref-type="fig"}). Two-way ANOVA indicated a significant influence of treatment \[*F*~(1,\ 131)~ = 36.3, *p* \< 0.001\] and time \[*F*~(5,\ 131)~ = 53.4, *p* \< 0.001\]. Analysis of hourly food intake during the 0--4 h period showed that the main anorexigenic effect of nesfatin-1~30−59~ occurred during the third and fourth hour post injection (−71 and −74%, respectively, compared to vehicle, *p* \< 0.05; Figure [6](#F6){ref-type="fig"}) pointing toward a delayed effect. In line with this assumption, parameters of the first meal were not significantly altered following nesfatin-1~30−59~ compared to vehicle (Table [5](#T5){ref-type="table"}).

![**Nesfatin-1~30−59~ reduces food intake for 8 h in ***ad libitum*** fed diet-induced obese rats**. Nesfatin-1~30−59~ (0.9 nmol/rat) injected intracerebroventricularly decreased dark phase food intake in the first 4 h period post injection, an effect that lasted for 8 h compared to vehicle (5 μl dd H~2~O). Food intake was assessed using an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g bw)/4 h periods **(A)** and cumulative food intake over a period of 24 h **(B)**. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 vs. vehicle; ^\*\*^*p* \< 0.01 vs. vehicle; ^\*\*\*^*p* \< 0.001 vs. vehicle.](fnins-09-00422-g0005){#F5}

![**Nesfatin-1~30−59~ reduces food intake in the third and fourth hour post icv injection in diet-induced obese rats**. Nesfatin-1~30−59~ injected intracerebroventricularly (0.9 nmol/rat) decreased dark phase food intake in *ad libitum* fed rats during the third and fourth hour post injection compared to vehicle (5 μl dd H~2~O). Food intake was assessed using an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g bw)/1 h periods. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 vs. vehicle.](fnins-09-00422-g0006){#F6}

###### 

**Nesfatin-1~30−59~ injected icv before the dark phase does not alter parameters of the first meal in diet-induced obese rats fed ***ad libitum*** with high fat diet**.

  **Parameter**                                                   **Group**    
  --------------------------------------------------------------- ------------ --------------
  Latency to first meal (min)                                     14.74±6.05   16.62±9.99
  Size of first meal (kcal/300 g bw)                              5.98±0.46    6.36±0.89
  Duration of first meal (min)                                    12.96±3.11   13.54±2.85
  Eating rate of first meal (cal/300 g bw/min)                    71.91±8.76   60.26±12.93
  Inter-meal interval (min)                                       80.66±9.92   128.10±24.60
  Satiety ratio after first meal (min/kcal/300 g bw food eaten)   13.76±1.77   22.50±5.00

*icv, intracerebroventricular; mean ± sem; n = 11/group; p \> 0.05*.

Based on the finding that nesfatin-1~30−59~ already decreased food intake in DIO rats during the 0--4 h period post injection, the microstructure was analyzed during this period. Nesfatin-1~30−59~ (0.9 nmol/rat, icv) reduced bout frequency (−33%, *p* \< 0.05; Figure [7C](#F7){ref-type="fig"}), meal frequency (−27%, *p* \< 0.05; Figure [7D](#F7){ref-type="fig"}), and eating rate (−35%, *p* \< 0.01; Figure [7G](#F7){ref-type="fig"}), while bout size (Figure [7A](#F7){ref-type="fig"}), meal size (Figure [7B](#F7){ref-type="fig"}), meal duration (Figure [7F](#F7){ref-type="fig"}), and the time spent in meals (Figure [7H](#F7){ref-type="fig"}) were not significantly affected compared to vehicle (*p*\>0.05). Moreover, inter-meal intervals (+53%, Figure [7E](#F7){ref-type="fig"}) and the satiety ratio (+81%, Figure [7I](#F7){ref-type="fig"}) were increased following icv injection of nesfatin-1~30−59~ (*p* \< 0.01 vs. vehicle).

![**Nesfatin-1~30−59~ decreases meal frequency, while meal size is not altered in diet-induced obese rats**. DIO rats fed high fat diet were injected intracerebroventricularly with nesfatin-1~30−59~ (0.9 nmol/rat) or vehicle (5 μl dd H~2~O) and the food intake microstructure assessed using an automated episodic food intake monitoring system. During the period of 0--4 h post injection, nesfatin-1~30−59~ reduced bout frequency **(C)**, meal frequency **(D)**, and eating rate **(G)**, while bout size **(A)**, meal size **(B)**, meal duration **(F)**, and the time spent in meals **(H)** were not altered compared to vehicle. Inter-meal intervals **(E)** and the satiety ratio **(I)** were increased following nesfatin-1~30−59~. Each bar represents the mean ± sem. ^\*^*p* \< 0.05 and ^\*\*^*p* \< 0.01 vs. vehicle.](fnins-09-00422-g0007){#F7}

The combined analysis of food intake data of rats fed control or high fat diet using Three-way ANOVA indicated a significant influence of diet \[*F*~(1,\ 257)~ = 83.5, *p* \< 0.001\], time \[*F*~(5,\ 257)~ = 108.1, *p* \< 0.001\], and interaction of diet and time \[*F*~(5,\ 257)~ = 10.6, *p* \< 0.001\] as well as an interaction of treatment and time \[*F*~(5,\ 257)~ = 2.6, *p* \< 0.05\].

Discussion {#s5}
==========

In the present study we investigated the effect of nesfatin-1~30−59~ on feeding behavior in rats under normal weight and diet-induced obese conditions. Nesfatin-1~30−59~ injected icv reduced dark phase food intake in normal weight rats fed a standard rodent diet. This effect was delayed in onset as parameters of the first meal were not altered with a maximum reduction of food intake observed during the fifth hour post injection and long lasting as it resulted in a reduction of cumulative food intake over the 24 h observation period. These data are in accordance with a previous study in rats where the main reduction following icv full length nesfatin-1~1−82~ was observed during the third hour post injection and also observed over the whole measurement period of 6 h (Stengel et al., [@B28]). The difference in the onset of action (third hour after nesfatin-1~1−82~ vs. fifth hour after nesfatin-1~30−59~) may be due to differential diffusion capacities following icv injection and---more importantly---differential interaction with the yet unknown nesfatin-1 receptor. Lastly, also the interaction with (an) additional receptor(s) has to be considered.

Interestingly, higher doses of nesfatin-1~30−59~ were needed to induce an anorexigenic effect. While nesfatin-1~1−82~ injected icv reduced food intake in rats following injection of 5 pmol, nesfatin-1~30−59~ exerted an anorexigenic effect after icv injection of 0.9 nmol/rat. This difference is likely to result from differential ligand-receptor interaction with full length nesfatin-1~1−82~ being more potent to induce the food intake inhibitory effect at low doses. Whether the difference in potency is due to more selective binding of nesfatin-1~1−82~ to the receptor, slower dissociation or a more potent stimulation of the receptor compared to nesfatin-1~30−59~ will have to be investigated in future studies. The effective dose observed here in rats is comparable to the anorexigenic doses described before in mice (0.3 and 0.9 nmol/mouse nesfatin-1~30−59~ icv; Stengel et al., [@B31]).

After establishing nesfatin-1~30−59~ also as an active fragment of nesfatin-1~1−82~ to reduce food intake in rats we investigated the underlying food intake microstructure. Nesfatin-1~30−59~ injected icv reduced food intake by reducing meal size, while meal frequency and inter-meal intervals were not altered. This pattern indicates an increase of satiation (earlier termination of a meal), whereas satiety (later initiation of a new meal after one meal is completed) is not affected. This pattern is different from the one observed before for mice where satiety (reduction in meal frequency) was induced while satiation (meal size was not altered) was not affected by icv nesfatin-1~30−59~ (Stengel et al., [@B31]). This difference points toward species differences and highlights the need for cautious translation of results from one species to another. Interestingly, in mice full length nesfatin-1~1−82~ injected icv increased both satiation and satiety (Goebel et al., [@B12]). This different pharmacodynamics is likely due to a differential receptor binding of full length nesfatin-1~1−82~ and its active core, nesfatin-1~30−59~.

Early on, the downstream signaling of NUCB2/nesfatin-1 has been investigated. It has been shown that oxytocin is involved in the mediation of nesfatin-1~1−82~\'s anorexigenic effect as nesfatin-1~1−82~ activates oxytocin containing neurons in the paraventricular nucleus of the hypothalamus (PVN) and central administration of the oxytocin-receptor antagonist, H4928 abolished the food intake reduction induced by nesfatin-1~1−82~ in rats (Maejima et al., [@B19]). Moreover, an involvement of proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) has been indicated as well based on the following observations: First, nesfatin-1~30−59~ was shown to upregulate the mRNA expression of POMC and CART in mice (Shimizu et al., [@B26]). Second, blockade of α-melanocyte stimulating hormone (α-MSH) signaling, a major anorexigenic cleavage product of POMC (Schwartz et al., [@B25]), using the melanocortin receptor 3/4 antagonist, SHU9119 also blocked nesfatin-1~1−82~\'s anorexigenic effect (Oh-I et al., [@B22]). Third, brain ventricular injection of the melanocortin receptor 3/4 agonist, MTII decreased food intake by reducing meal size, while no effect on meal frequency was observed (Azzara et al., [@B4]; Berthoud et al., [@B5]), resembling the pattern of action observed after icv injection of nesfatin-1~30−59~ in the present study. Since oxytocin increases the release of POMC in the nucleus of the solitary tract (NTS), nesfatin-1~30−59~ is likely to act *via* an oxytocin → POMC → α-MSH/melanocortin receptor 3/4 pathway to inhibit food intake in rats.

Despite the fact that NUCB2/nesfatin-1 is predominantly expressed in the stomach (Stengel et al., [@B30]), the role of peripheral NUCB2/nesfatin-1 is far from being clear. While one study reported an anorexigenic effect following ip injection of nesfatin-1~30−59~ in mice (Shimizu et al., [@B26]), other studies in rats (Stengel et al., [@B28]), or mice (Goebel et al., [@B12]) did not detect any effect. Similarly, in the present study we did not find an anorexigenic effect of nesfatin-1~30−59~ injected ip in normal weight rats although up to 30-fold higher doses were used. This difference may be due to species differences (mice vs. rats) or different doses used (up to \~40 nmol/mouse vs. \~22 nmol/rat in the present study). However, these findings clearly point toward a central mode of action of nesfatin-1 to reduce food intake, while peripheral nesfatin-1 is likely to have a different main effect such as glucose control (Nakata and Yada, [@B21]).

Signaling of several food intake regulatory hormones is altered under conditions of obesity (Hellström, [@B15]). These changes encompass a decrease in circulating ghrelin levels (Ariyasu et al., [@B2]) which may represent a compensatory action to prevent further overeating. On the other side, the postprandial release of anorexigenic signals such as peptide YY (Xu et al., [@B39]) is blunted under these condition which is likely to result in reduced anorexigenic signaling. Therefore, we investigated the effect of nesfatin-1~30−59~ also in DIO rats fed a high fat diet. The anorexigenic effect of nesfatin-1~30−59~ was retained in DIO rats with a delayed onset (parameters of the first meal were not changed) and a long duration of action. Interestingly, the main food intake inhibitory effect was already observed during the third hour post injection (−71%), while in normal weight rats the main reduction occurred later in the fifth hour post nesfatin-1~30−59~ icv injection (−75%). Moreover, the effect translated into a reduction of food intake over a 20 h period (−13%), while in normal weight rats the effect lasted for 20 h (−12%). Lastly, the underlying food intake microstructure was different in DIO rats compared to normal weight rats with a decrease in meal frequency and an unaltered meal size under conditions of high fat feeding indicating an increase of satiety while satiation is not altered. Taken together, these findings give rise to differential receptor binding, altered diffusion and---most importantly---point toward a differential downstream signaling under conditions of DIO compared to normal weight rats.

Interestingly, it was recently shown that rats fed a high fat diet display significantly lowered plasma NUCB2/nesfatin-1 levels (Haghshenas et al., [@B14]; Mohan et al., [@B20]). Although the cellular action on the so far unknown receptor is yet to be established, the chronically reduced circulating NUCB2/nesfatin-1 levels may result in a sensitization of the receptor and lead to a stronger/more rapid response to icv nesfatin-1~30−59~. Early on, it was shown that nesfatin-1~1−82~ acts in a leptin-independent fashion (Oh-I et al., [@B22]; Maejima et al., [@B19]). However, the corticotropin releasing factor (CRF) receptor 2, shown to play a role in nesfatin-1~1−82~\'s anorexigenic signaling under normal weight conditions (Stengel et al., [@B28]), may be important under DIO conditions as well. An earlier study showed that brain injection of the selective CRF~2~ agonist, urocortin 3 (1 μg/rat) reduced food intake with a delayed onset (between 3 and 4 h) by decreasing meal frequency while meal size was not altered in rats (Fekete et al., [@B10]), a pattern very similar to the one observed following icv nesfatin-1~30−59~ observed under DIO conditions in the present study. The predominance of the CRF~2~ downstream signaling pathway in the mediation of nesfatin-1~30−59~\'s anorexigenic action might result from reduced processing of POMC to α-MSH under conditions of obesity due to reduced prohormone convertase two levels (Çakir et al., [@B6]).

In conclusion, these results provide pharmacological evidence that nesfatin-1~30−59~ is the active core of full length nesfatin-1~1−82~ also in rats that reduces food intake in normal weight rats fed standard rodent diet as well as DIO rats fed a high fat diet. Interestingly, the food intake microstructure differs with an increase of satiation under normal weight and an induction of satiety under DIO conditions. This may result from a downstream nesfatin-1~30−59~ → oxytocin → POMC → α-MSH/melanocortin receptor 3/4 signaling in normal weight rats while in DIO rats the nesfatin-1~30−59~ → CRF/CRF~2~ pathway may predominate. The effect of nesfatin-1~30−59~ is centrally mediated as ip injection of higher doses had no effect. Therefore, the main effect of peripheral nesfatin-1 remains to be established.
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